Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification

• Published in: Epigenomics Vol. 11; no. 8; pp. 885 - 897
• Main Authors: Krause, Christin, Sievert, Helen, Geißler, Cathleen, Grohs, Martina, El Gammal, Alexander T, Wolter, Stefan, Ohlei, Olena, Kilpert, Fabian, Krämer, Ulrike M, Kasten, Meike, Klein, Christine, Brabant, Georg E, Mann, Oliver, Lehnert, Hendrik, Kirchner, Henriette
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.06.2019
• Subjects: ABCG1; Adipose tissue; Biomarkers; Bisulfite; Blood; Deoxyribonucleic acid; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); DNA; DNA methylation; Epigenetics; EWAS; Gene expression; Genomes; Homeostasis; Insulin; Insulin resistance; Lipids; Liver; Markers; Measurement methods; Metabolism; Obesity; Pathogenesis; Single-nucleotide polymorphism; SREBF1; Studies; Type 2 diabetes; visceral adipose tissue; Type 2 diabetes; SREBF1; EWAS; liver; DNA methylation; blood; ABCG1; visceral adipose tissue
• ISSN: 1750-1911; 1750-192X
• DOI: 10.2217/epi-2018-0159

Validation of epigenome-wide association studies is sparse. Therefore, we evaluated the methylation markers cg06500161 ( ) and cg11024682 ( ) as classifiers for diabetes stratification. DNA methylation was measured in blood (n = 167), liver (n = 99) and visceral adipose tissue (n = 99) of nondiabetic or Type 2 diabetic subjects by bisulfite pyrosequencing. DNA methylation at cg11024682 in blood and liver correlated with BMI. Methylation at cg06500161 was influenced by the adjacent SNP rs9982016. Insulin-resistant and sensitive subjects could be stratified by DNA methylation status in blood or visceral adipose tissue. DNA methylation at both loci in blood presents a promising approach for risk group stratification and could be valuable for personalized Type 2 diabetes risk prediction in the future.